(HealthDay News) — In patients with heavily pretreated relapsed/refractory multiple myeloma with relapse after bispecific antibody (BiAb) T-cell redirection therapy, subsequent T-cell redirection therapy is feasible as salvage treatment, according to a study published in Blood Advances.
Tarek H. Mouhieddine, MD, from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues identified 58 patients with multiple myeloma whose disease was progressing after a BiAb trial.
Progression-free survival (PFS) to first (PFS1) and second (PFS2) salvage therapy and overall survival (OS) were estimated for the patients (median age, 67 years).
The patients had a median of 6 lines of prior therapy. Most (89%) were triple-class refractory, and 44% were penta-refractory. Patients were followed for a median of 30.5 months after the BiAb trial and received a median of 2 additional salvage therapies.
There were 19 patients who received T-cell redirection therapy as first salvage, with 10 patients receiving BiAb and 9 receiving chimeric antigen receptor (CAR) T-cell therapy. There were 10 patients who received T-cell redirection as second salvage.
T-cell redirection therapy was feasible as first or second salvage and was associated with a median PFS1 of 28.9 months, a median PFS2 of 30.9 months, and a 2-year OS rate of 62%.
“This study shows patients relapsing after initial BiAb therapy can benefit from a second BiAb or CAR T-cell therapy,” a study author said in a statement.
Several authors disclosed financial ties to various pharmaceutical companies.